4 results about "Nutritive Sweeteners" patented technology

A composition and a use thereof. The composition comprises brazzein, stevioside, and erythritol, wherein the mass ratio of brazzein to stevioside to erythritol is (2-48):(5-160):(5000-80000). The composition can be widely used in food and beverage products and daily chemical care products as an alternative of sucrose / other sweeteners, thereby reducing potential health risks caused by excessive intake of nutritive sweeteners.

The present disclosure provides novel compositions comprising pectin, a first xanthan gum, and optionally a second xanthan gum. These compositions can be used to improve the mouthfeel properties of non-nutritive sweeteners, such as steviol glycosides and blends thereof, in food and beverages containing the same.

The present application relates to the field of metabolic engineering, and provide a method for high-efficiency synthesis of D-allulose by Escherichia coli using nutritional sweetener-sucrose, wherein D-allulose is produced by recombinant Escherichia coli using cheap and traditional nutritional sweetener, and wherein Escherichia coli JM109(DE3) is used as a chassis host, wherein a path for producing D-allulose from sucrose is constructed by introducing exogenous proteins sucrose-6-phosphate hydrolase CscA, sucrose permease CscB, fructokinase CscK, D-allulose-6-phosphate epimerase AlsE and D-allulose-6-phosphate phosphatase A6PP into wild-type Escherichia coli to realize co-expression, and wherein the substrate utilization rate is improved by introducing ptsG-F and knocking out ptsG, fruA, ptsI and ptsH to reprogram the sugar transmembrane transport pathway.

An orally disintegrating tablet of amlodipine for oral administration comprising: a) amlodipine or pharmaceutically acceptable salts thereof, is present in an amount ranging from 2 to 10% w / w; b) at least one diluent; c) at least one disintegrant is present in the range from 1 to 10% w / w; d) at least one lubricant is present in the range from 0.2 to 7% w / w; e) at least one non-nutritive sweetener is present in the range from 0.1 to 7% w / w; f) at least one or more pharmaceutically acceptable excipients; wherein the ratio of combination of diluents to disintegrant is in the range from 15:1 to 40:1; and wherein orally disintegrating tablet is stable for at least three months under storage conditions of 25°C / 60% RH and 40°C / 75% RH.